On this episode of the SO files, Brad and Linda dive into the basics of radiation oncology, with the goal to give a basis of understanding for different radiation therapy regimens. The episode begins with an overview of what is radiation oncology and what are the major types of radiation oncology we should know about. For this episode, the SO files are excited to welcome on repeat guest Dr. Parag Parikh, Associate Professor of Radiation Oncology, and chief of GI radiation oncology at Washington University in St. Louis School of Medicine.
Interview with Dr. Parikh: 13:00
Geraldine Jacobson, Alexander Chi, Dongxu Wang, Phillip Devlin, Ivan Buzorovic, Antonio Damato, Desmond O’Farrell, Alexandra J. Stewart
A recently published textbook covering all aspects of surgical oncology, with this specific chapter focusing on radiation oncology basics. The chapter runs through the various forms of radiation therapy, explaining both the utility and limitations of each technique.
Deborah E. Citrin
A recently published (September 2017) and well written review article in the NEJM , highlighting several forms of radiation oncology and the mechanisms behind them.
Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H.
Phase 2 RTOG 0236 trial of stereotactic body radiotherapy for cT1-2N0M0 medically inoperable NSCLC patients. Only 59 patients enrolled, with 55 evaluable, and median follow up 34.4 months. Estimated 3 year local control was 97.6%.
Rosen JE, Salazar MC, Wang Z, Yu JB, Decker RH, Kim AW, Detterbeck FC, Boffa DJ.
Rosen and colleagues looked at the national cancer database for healthy patients that were surgical candidates with cT1-2N0 lung cancer. They found that patients undergoing lobectomy did better than those receiving stereotactic radiotherapy. They went on to propensity score match lobectomy and stereotactic body radiation therapy patients, with lobectomy conferring a 59% 5 year survival vs 29% for stereotactic radiotherapy.
Ongoing phase III RCT comparing sorafenib + stereotactic body radiotherapy versus sorafenib alone for patients with hepatocellular carcinoma who are not suitable for surgery, transplant or radiofrequency ablation.
This episode was produced by Brad Krasnick and Linda Jin. You can email us at firstname.lastname@example.org. Thanks for listening!